Alaunos amends license with Precigen; returns CAR/IL-12 rights, eliminates all payment obligations

Alaunos Therapeutics, Inc.

Alaunos returns exclusive rights to CAR (CD19 & BCMA) and IL-12 products to Precigen; retains TCR and Sleeping Beauty licenses.
All Alaunos development and commercialization obligations under the license are eliminated.
Alaunos no longer owes milestone payments (up to $52.5M per program) or royalties; Precigen's royalty obligations also removed.
Annual license payment reduced from $100,000 to $75,000.
License term now tied to expiration of last valid patent claim instead of later of patent life or 12 years post-first commercial sale.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Alaunos Therapeutics, Inc. amended Amended and Restated Exclusive License Agreement with Precigen, Inc. valued at $75,000 (effective 2023-04-03).

Action: amendment
Agreement: license
Counterparty: Precigen, Inc.
Value: $75,000
Effective: 2023-04-03

Exact text from the filing

On April 3, 2023, Alaunos Therapeutics, Inc. (the “Company”) and Precigen, Inc. (“Precigen”) entered into the Amended and Restated Exclusive License Agreement (the “A&R Agreement”) which amended and restated in its entirety the original Exclusive License Agreement, dated October 5, 2018, as amended (the “Original Agreement”).

View on SEC.gov

Browse all material agreements →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-091011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.